Clear Gene GTM brain

category

market profile

• text: Clear Gene describes using genomics and machine learning for residual solid tumor detection, including breast cancer.
• text: An independent public-record review reported no registered trial or peer-reviewed study for its margin test; current clinical availability and validation require direct confirmation.

personas

• title: Breast surgeon or surgical oncology lead
  pains:

  • Uncertain surgical margins can lead to further procedures
  • Needs evidence that any new assessment improves decisions for a defined patient population
• title: Molecular pathology lab director
  pains:

  • Different PCR instruments and assays require separate interpretation workflows
  • Lab expansion is constrained by throughput, validation and existing equipment
• title: Hospital diagnostics procurement lead
  pains:

  • Needs current validation, regulatory status, instrument compatibility and reimbursement before adoption

icp

• text: Breast cancer centers and surgical oncology programs investigating residual tumor assessment, contingent on clinical evidence and product availability.
• text: Clinical molecular labs operating PCR instruments and evaluating analysis software or sample preparation workflows; company size is unspecified.

message pillars

• text: Apply molecular methods to residual solid tumors.
• text: Support higher throughput using existing lab equipment.
• text: Consolidate interpretation for labs running multiple instruments.

objections

• objection: Is the cancer test validated and available for our intended use?
  response: Request current study results, regulatory status and intended-use documentation; do not assume clinical availability.
• objection: Will our lab need new equipment?
  response: The company describes use with existing equipment; ask for validation and compatibility for specific instruments and assays.
• objection: What will testing cost and will insurers cover it?
  response: Request current pricing and payer coverage; neither was established in the public sources reviewed.

competitors

• name: Dilon Medical Technologies
  why: MarginProbe addresses intraoperative breast surgical margin assessment using a different technology.
• name: Natera
  why: Signatera addresses molecular residual disease via blood testing, a related but distinct clinical workflow.
• name: Guardant Health
  why: Guardant Reveal addresses residual disease with blood testing, rather than tissue margin assessment.

influencers

• name: Brandon Steelman
  url: https://f.inc/portfolio/clear-gene/
  why: Founder of Clear Gene.

keywords

• breast cancer surgical margin test
• residual breast tumor assay
• lumpectomy margin assessment
• molecular residual disease test
• clinical PCR interpretation software
• RNA cancer diagnostics

voice

• Scientific and explanatory
• Low-key
• Patient impact focused

signals

• text: A breast surgery program is evaluating approaches to reduce positive margins and repeat operations.
• text: A molecular lab is consolidating interpretation across PCR instruments or seeking more sample throughput.

stack

• PCR

pricing

motion

confidence

Founders

• name: Brandon Steelman
  title: Founder
  role: Founder